According to an article by Andrew Pollack in today’s issue of the New York Times, a company called Osisris Therapeutics has achieved the first-ever approval to market a therapy based on stem cells — in Canada, for children with a condition known as graft versus host disease or GvHD, which is a well-recognized complication of bone marrow transplantation. You can also click here to see the media release from the company itself.
Why may this be of relevance to prostate cancer? Because many researchers believe that as our understanding of the management of cancer improves, it may be possible to use stem cell-based therapies to prevent recurrences of some cancers in high-risk patients without the side effects associated with long-tyerm hormone- and chemotherapy-based regimens. At least now there is an approval of one stem cell-based therapeutic regimen somewhere in the world, which will help other regulatory authorities to move such treatments to market in an efficient manner.